Welcome to our dedicated page for HYPERFINE news (Ticker: HYPR), a resource for investors and traders seeking the latest updates and insights on HYPERFINE stock.
Hyperfine, Inc. (Nasdaq: HYPR) is a health technology and medical device company that focuses its news flow on developments around the Swoop® Portable MR Imaging® System, an FDA-cleared, portable, ultra-low-field brain MRI platform. Company press releases emphasize regulatory milestones, clinical studies, financial results, and global health initiatives tied to this AI-powered portable MRI technology.
Investors and clinicians following HYPR news can expect regular updates on clinical research and indication expansion efforts. Recent announcements include the enrollment of the first patient in the Contrast PMR study, a prospective, multi-center trial designed to evaluate contrast-enhanced ultra-low-field portable MRI to support a future FDA submission for expanded intended use of the Swoop® system with gadolinium-based contrast agents. Other clinical news has highlighted the PRISM PMR study, which evaluates the Swoop® system’s use in neurosurgical operating room settings, and a peer-reviewed publication describing the economic impact of integrating the Swoop® system into acute hospital care.
Hyperfine’s news feed also features regulatory and market access updates, such as regulatory approval of the Swoop® system in India by the Central Drugs Standard Control Organization (CDSCO), as well as CE Mark and UKCA Mark approvals for its Optive AI™ software. Financial and corporate news includes quarterly and preliminary unaudited financial results, capital raises through public offerings, participation in healthcare conferences, and business updates related to the commercial rollout of the next generation Swoop® system and Optive AI™ software.
For those tracking HYPR, the news stream provides insight into the company’s progress in hospital and neurology office adoption, its international expansion, and its collaborations on global brain health projects such as the UNITY initiative. Bookmarking this page allows readers to monitor how Hyperfine’s clinical, regulatory, and financial developments evolve over time.
Hyperfine, creator of the Swoop® Point-of-Care MRI System™, recently announced the acceptance of twelve abstracts for presentation at the ISMRM and ISMRT annual meeting in Toronto from June 3–8, 2023. The research, conducted by teams from prestigious institutions like UPenn and NYU, includes advanced topics in MRI technology. The Swoop® system aims to enhance patient outcomes by providing portable, ultra-low-field brain imaging at the bedside. The ongoing research supports Hyperfine's mission to revolutionize patient care through accessible MRI technology.
Hyperfine (Nasdaq: HYPR), a leader in medical technology, announced its participation in the 5th Annual Evercore ISI HealthCONx Conference scheduled for November 30, 2022, at 9:15 AM Eastern Time. The company will present their groundbreaking Swoop®, the world’s first FDA-cleared portable MRI system, which enhances patient access to MRI diagnostics.
Interested individuals can view the live and archived webcast via the Investors section of their website.
Hyperfine, Inc. (Nasdaq: HYPR) reported Q3 2022 revenues of $2.348 million, up from $0.371 million year-over-year. The net loss improved to $13.171 million, or $0.19 per share, compared to a loss of $16.392 million, or $8.66 per share in Q3 2021. The company installed 10 Swoop systems in the quarter, totaling 30 installations for the year. Management expects full-year revenue between $7 million and $8 million and anticipates 35 to 45 commercial units installed in 2022, reflecting ongoing growth despite net losses.
Hyperfine, Inc. (Nasdaq: HYPR) announced it will release its third-quarter 2022 financial results on November 10, 2022. Following the release, management will conduct a conference call at 1:30 PM PT / 4:30 PM ET. Interested participants can register online to listen. Hyperfine is known for its innovative Swoop® system, the first portable MRI device cleared by the FDA, which allows for quick diagnostics and treatments in various healthcare settings, improving patient access to essential imaging services.
Hyperfine, Inc. (Nasdaq: HYPR) announced Maria Sainz as its new President and CEO, effective October 24, 2022. Sainz, with over 30 years of experience in the medical device sector, has previously led multiple companies and has been a board member since Hyperfine's Nasdaq listing. She aims to expand the adoption of Hyperfine's portable MRI system, Swoop, which is already installed in over 90 locations globally. The company seeks to enhance medical imaging access worldwide while maintaining a disciplined spending approach to drive growth.
Hyperfine (Nasdaq: HYPR) announced management's participation in two upcoming conferences. Scott Huennekens and Alok Gupta will present at the Gilmartin Group Emerging Growth Company Showcase on August 31, 2022, at 1:00 PM EDT. A live webcast will be available. Gupta and Khan Siddiqui will present at the 2022 Wells Fargo Healthcare Conference on September 8, 2022, at 9:10 AM EDT, with a live and archived version accessible online. Hyperfine is known for Swoop, the first FDA-cleared portable MRI system, enhancing patient access to diagnostic imaging.
Hyperfine, Inc. (Nasdaq: HYPR) reported Q2 2022 revenues of $1.533 million, up from $0.358 million in Q2 2021, reflecting strong adoption of its portable MRI system, Swoop. However, the company faced a net loss of $23.159 million, compared to a loss of $14.580 million in the same period last year. Hyperfine installed 9 new systems, bringing total installations to 47. The company anticipates 2022 revenues of $7 million to $8 million and plans to install 35 to 45 commercial units. Positive developments include FDA clearances for system enhancements and a partnership with Viz.ai for improved patient care.
Viz.ai has partnered with Hyperfine, Inc. (NASDAQ: HYPR) to enhance healthcare delivery by integrating AI-powered disease detection with Hyperfine's portable MRI system, Swoop. This collaboration aims to expedite neuroimaging, allowing clinicians to access MRI diagnostics at the patient's bedside, significantly reducing wait times and improving decision-making in time-critical situations. The partnership is expected to enhance patient outcomes and streamline clinical workflows, particularly in neuro ICUs, emphasizing the importance of timely medical intervention.
Hyperfine, Inc. (Nasdaq: HYPR) will announce its financial results for Q2 2022 on August 10, 2022, at a webcast starting at 1:30 p.m. PT / 4:30 p.m. ET. The company is known for Swoop®, the first FDA-cleared portable MRI system, aimed at enhancing patient access to critical imaging. Designed for versatility, Swoop provides rapid diagnostics in various settings, with high-quality images at lower costs.
Hyperfine, a pioneering medical device company, unveiled an advanced software upgrade for its Swoop® portable MRI system at HA Connect! on July 14, 2022. This enhancement allows brain scans for young hydrocephalus patients in under three minutes without ionizing radiation, addressing health risks associated with CT scans. With over 40,000 hospital admissions yearly due to hydrocephalus, this software aims to improve diagnostic efficiency and patient safety. The FDA recently cleared this update, demonstrating Hyperfine's commitment to innovative healthcare solutions.